Home   Business   Article

Subscribe Now

Owlstone Medical’s Atlas database is boost for breath biopsy




Owlstone Medical has unveiled the Breath Biopsy VOC Atlas, a catalogue of validated and quantitated volatile organic compounds (VOCs) found on breath.

Billy Boyle, co-founder and CEO of Owlstone Medical. Picture: Keith Heppell
Billy Boyle, co-founder and CEO of Owlstone Medical. Picture: Keith Heppell

The global leader in breath biopsy for applications in early disease detection and precision medicine has catalogued the validated and quantitated volatile organic compounds (VOCs) found on breath, and included insight and scientific context into the Atlas’ description of the molecules.

The Breath Biopsy VOC Atlas has been built through detailed analysis of breath samples representing a diverse mix of ages and ethnic backgrounds to identify and quantify commonly seen chemicals originating from breath. At over 150 chemicals and growing, the Breath Biopsy VOC Atlas represents the largest available database of identified VOCs on breath, their normal levels, and biological interpretation.

The Atlas will form the basis of future biomarker discovery at Owlstone through incorporation into Owlstone’s Breath Biopsy OMNI platform. By now being able to analyse VOCs with baseline chemical levels known, alterations related to disease can be more easily recognised and developed into biomarkers. Further, reduced variability, improved data quality and higher throughput will provide the best chance to identify biomarkers in customer studies and Owlstone’s own test development efforts.

Owlstone Medical social card
Owlstone Medical social card

Billy Boyle, co-founder and CEO at Owlstone Medical, said: “Owlstone Medical is leading the way in overcoming the challenges that, to date, have held the breath field back.

“Our vision is to be the leading source for biomarker discovery on breath, and the addition of Atlas to the OMNI platform allows identification of promising VOCs with a higher degree of confidence.

“In this way, we further enhance our ability to provide the best discovery solutions available to customers and maximise the chances of finding biomarkers with the potential to be translated into clinically valuable tests.”



Comments | 0
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies - Learn More